Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Open-Label Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of BAX69 In Subjects With Malignant Solid Tumors

Trial Profile

A Phase 1 Open-Label Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of BAX69 In Subjects With Malignant Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 03 May 2019

At a glance

  • Drugs Imalumab (Primary)
  • Indications Adenocarcinoma; Colon cancer; Rectal cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Baxalta; Shire
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 11 Oct 2016 Final results presented at the 41st European Society for Medical Oncology Congress (2016).
    • 13 Sep 2016 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top